NextDocs Announces Partnership with Thomson Reuters
Philadelphia, PA- September 17, 2009
NextDocs Corporation announced enhancements to their partnership with Thomson Reuters, a leading source of intelligent information for businesses and professionals. Together, the companies have developed and demonstrated effective integration between the NextDocs Document and Quality Management System and the Thomson Reuters Liquent Regulatory software platform, providing a comprehensive solution for managing regulatory content from authoring to publishing and submission. In addition, the two companies also announced that NextDocs will support the Liquent SmartScribe® set of document templates from Thomson Reuters.
The integration between the NextDocs Document and Quality Management System and the Liquent InSight Platform allows the two systems to work from a common set of SharePoint-based documents. With SharePoint as a common repository, NextDocs system and theLiquent Regulatory Software are able to interact with one another; for example, organizations can access NextDocs documents housed in SharePoint and build an eCTD structure utilizing Thomson Reuters Liquent InSight Platform.
"Our Liquent InSight platform...provide[s] a single authoritative platform, which allows users to manage regulatory information through all stages of development, from early submissions to marketed registrations," said Rick Riegel, Vice President and General Manager, Services and Software Solutions at Thomson Reuters.
As part of the enhanced partnership, NextDocs will be offering Liquent SmartScribe® from Thomson Reuters. These templates enable users to create common technical documents quickly, efficiently and in a constant standard. The user friendly templates help to ensure all documents comply with format requirements.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
